Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

There are no files associated with this record.

Title Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
Author Patel, A; MacMahon, S; Chalmers, J; Neal, B; Billot, L; Woodward, M; Marre, M; Cooper, M; Glasziou, P; Grobbee, DE; Hamet, P; Harrap, S; Heller, S; Liu, LS; Mancia, G; Mogensen, CE; Pan, CY; Poulter, N; Rodgers, A; Williams, B; Bompoint, S; Galan, B de; Joshi, R.; Travert, F; Ferrannini, E; Hamet, P; Collins, R; Holman, R; Sandercock, P; Sleight, P; Fulcher, G; Adams, M; Branley, M; Jenkins, B; Louis, D; Lowe, H; Luo, W; McCormack, A; Mitchell, P; Ong, S; Pollock, C; Watson, J; Wong, T; Billot, L; Bompoint, S; Colman, S; Francis, L; Heritier, S; Li, Q; Ninomiya, T; Pillai, A; Travert, F; Baksi, A; Bao, YQ; Cutfield, R; Dumas, R; Fovenyi, J; Fu, HJ; Huang, H; Jia, PH; Khir, A; Krahulec, B; Li, CL; Li, J; Litonjua, A; MacIsaac, R; Placzkiewicz-Jankowska, E; Quirk, S; Southern, S; Tack, C; Tandon, N; Xu, ZR; Zhang, JC; Zhang, Z; Zou, XM; Prato, S Del; Flynn, S; Monaghan, H; Allen, S; Bi, YF; Carreras, A; Cass, A; Chen, T; Currie, R; Davies, P; Du, X; Fathers, J; Gibb, S; Girgis, S; Graziano, A; Heritier, S; Hibbard, J; Hough, S; Huynh, A; Jan, S; Jardine, M; Jayne, K; Davoren, Peter Michael; et al.
Journal Name The New England Journal of Medicine
Year Published 2008
Place of publication United States of America
Publisher Massachusetts Medical Society
Abstract The prevalence of Type 2 diabetes is increasing rapidly and is associated with significant cardiovascular adverse effects. The authors tested the hypothesis that, in patients with type II diabetes, intensive glucose control as evidenced by lowering the glycated hemoglobin level to to ≤6.5% would result in lower rates of major microvascular and macrovascular events. There were 11,140 patients with Type 2 diabetes who were randomly assigned to undergo standard glucose control or intensive glucose control. Intensive glucose control was achieved with the use of gliclazide (modified release) and other drugs as required to reach a glycated hemoglobin ≤6.5%. Primary end points were composites of major microvascular events (new or worsening nephropathy or retinopathy) or macrovascular events (death from cardiovascular causes, non-fatal myocardial infarction, or non-fatal stroke). End points were assessed both jointly and separately.
Peer Reviewed Yes
Published Yes
Publisher URI http://www.sciencedirect.com/science/journal/07415214
Alternative URI http://dx.doi.org/10.1016/j.jvs.2008.07.045
Volume 358
Issue Number 24
Page from 2560
Page to 2572
ISSN 0028-4793
Date Accessioned 2009-01-08
Date Available 2014-10-10T01:56:19Z
Language en_US
Faculty Griffith Health Faculty
Subject PRE2009-Epidemiology
URI http://hdl.handle.net/10072/26242
Publication Type Journal Articles (Refereed Article)
Publication Type Code c1

Show simple item record

Griffith University copyright notice